Eli Lilly (NYSE:LLY) just delivered one of the most impressive quarters in big pharma history, and the stock is responding.
Lilly is the maker of tirzepatide, sold as Mounjaro for type 2 diabetes and as Zepbound for weight loss -- though both have ...
The Investment Committee gives you their top stocks to watch for the second half.
Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...
Eli Lilly celebrated 150 years, growing from a small Indianapolis lab to a global pharmaceutical giant worth tens of billions ...
Eli-Lilly has launched India’s first disease-modifying Alzheimer’s drug, donenemab, under the brand name Lormalzi. Approved by the CDSCO in 2025, the treatment aims to slow cognitive decline in ...
U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India.
The Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded his company on May 10, 1876.
6don MSN
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.
The competition is far behind.
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly ...
Eli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, ...
Eli Lilly launches Lormalzi in India, a once-monthly Alzheimer's therapy for mild impairment. It targets amyloid plaques to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results